All articles tagged with #obesity treatment
A Wall Street Journal piece explains that GLP-1 weight-loss medications like Ozempic and Wegovy are intended as lifelong treatments for obesity, not quick lifestyle fixes; studies show most people who stop the drugs regain the lost weight within about 1.5 years, underscoring the need for ongoing treatment and monitoring.
A real-world analysis of 135,000+ patients on GLP-1 therapies (tirzepatide and semaglutide) found weight loss durability after discontinuation. Six months after stopping, about 28% of tirzepatide users regained weight, while 36% kept it off and 36% continued to lose; for semaglutide, ~33% regained, ~32% maintained, and ~35% still lost weight, with a median six‑month change of 0%. The findings suggest durability is possible in routine care and could support a disease-management approach, especially when paired with exercise counseling. Limitations include its observational nature and incomplete accounting for dose and lifestyle factors; results differ from some clinical trial findings and more research is needed to identify who maintains weight loss long-term.
Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.
A study from the University of Oxford found that stopping GLP-1 receptor agonist drugs like Wegovy and Ozempic leads to rapid weight regain and loss of health benefits within about 1.4 to 1.7 years, highlighting the need for comprehensive, long-term weight management strategies rather than short-term medication use.
Stopping GLP-1 weight-loss drugs causes weight regain four times faster than ending exercise, with most individuals returning to their original weight within 18 months, highlighting the need for long-term management strategies.
Novo Nordisk received FDA approval for Wegovy, the first oral GLP-1 medication for weight loss, which could significantly impact the obesity treatment industry by offering a more convenient option and potentially increasing market share amid rising competition and pricing pressures.
The FDA has approved the first daily oral medication version of Wegovy, a popular weight-loss drug, giving Novo Nordisk an advantage over Eli Lilly, whose similar drug is still under review. The pill, containing semaglutide, has shown significant weight loss in clinical trials and is expected to be available soon, potentially expanding access and reducing costs for obesity treatments.
The FDA has approved the first oral GLP-1 pill for weight loss, developed by Novo Nordisk, which offers a more convenient and potentially cheaper alternative to injections, with clinical trials showing significant weight loss results.
Pfizer will acquire Metsera for up to $10 billion after a bidding war with Novo Nordisk, with the deal expected to close soon. Metsera's stock fell over 15% following the announcement, despite its initial surge after going public in January. The acquisition aims to strengthen Pfizer's position in obesity treatment, leveraging Metsera's midstage GLP-1 drug and potential monthly therapies.
Pfizer is potentially leveraging its political connections, including ties with President Trump, to outbid Danish rival Novo Nordisk in an $8.5 billion deal for obesity biotech Metsera, amid concerns about overpaying and antitrust issues.
Scientists have discovered that the protein MRAP2 helps transport the hunger receptor MC4R to the cell surface, enhancing its ability to send satiety signals, which could lead to new obesity therapies.
Novo Nordisk's latest clinical trial shows that tripling the dose of its obesity drug semaglutide results in an average of 19% weight loss over 72 weeks, slightly below Eli Lilly's tirzepatide but still promising, as the company aims to strengthen its position in the competitive obesity market. Despite recent challenges and a 60% stock decline over the past year, analysts see potential upside, with NVO rated as a moderate buy and a 23.4% projected increase.
A clinical trial shows that a triple dose of a Novo Nordisk drug results in an average of 19% weight loss, highlighting its potential as an effective obesity treatment.
A population study in Denmark found that over half of adults without diabetes who start the weight-loss drug semaglutide discontinue it within a year, mainly due to high costs, adverse effects, and demographic factors, raising concerns about long-term effectiveness and accessibility of this obesity treatment.
Eli Lilly's shares dropped over 14% after its obesity drug forglipron underperformed expectations in late-stage trials, marking its worst day in decades, while competitors like Novo Nordisk saw gains amid ongoing development of weight loss medications.